Q1 2012 · 10-Q
Revenue$12.25M$12.25M +19.6% vs Q1 2011−61.9% vs Q4 2011
Net income—
EPS Diluted-$0.34-$0.34 N/M vs Q1 2011N/M vs Q4 2011
Operating Income-$35,636,000N/M
Operating Cash Flow-$43,062,000N/M
Free Cash Flowderived-$47,704,000N/M
Margins · derived
Operating margin-291.0%−109.8 pt vs Q1 2011
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q1 2012 | Q1 2011 | Q1 2010 |
|---|---|---|---|
| Revenue | $12.25M | $10.24M | $8.84M |
| Net Income | — | -$18.40M | -$16.25M |
| EPS Diluted | -$0.34 | -$0.19 | -$0.25 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ironwood Pharmaceuticals Inc · CIK 1446847 · Engraved from SEC EDGAR